Advertisement

Soaring generic drug prices draw Senate scrutiny

By Associated Press  |  November 21, 2014

Some low-cost generic drugs that have helped restrain healthcare costs for decades are seeing unexpected price spikes of up to 8,000%, prompting a backlash from patients, pharmacists and now lawmakers.

Another $2 billion-plus year for DOJ healthcare recoveries

Another $2 billion-plus year for DOJ healthcare recoveries

By Lisa Schencker  |  November 20, 2014

The Justice Department recovered $2.3 billion from alleged healthcare fraud schemes in fiscal 2014, down slightly from the $2.6 million it collected the year before, it announced Thursday morning.

Actavis to spend $66 billion on Allergan

By Associated Press  |  November 18, 2014

Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.

Vytorin trial shows modest cholesterol benefit with statin combo

By Sabriya Rice  |  November 17, 2014

The long-awaited results of a trial of the cholesterol-lowering drug Vytorin showed modest benefit and indicated that adding a non-statin drug to a statin therapy regimen may help high-risk patients with acute coronary syndrome safely achieve lower cholesterol levels.

Heart stents may require longer blood thinner use

By Associated Press  |  November 17, 2014

Millions of people with stents that prop open clogged heart arteries may need anti-clotting drugs much longer than the one year doctors recommend now. A large study found that continuing for another 18 months lowers the risk of heart attacks, clots and other problems.

HHS 340B drug discount program holds off on 'mega-reg'

HHS 340B drug discount program holds off on 'mega-reg'

By Jaimy Lee  |  November 14, 2014

HHS has scrapped plans to issue sweeping regulations clarifying the federal 340B drug discount program in light of a court ruling against another 340B rule challenged by the pharmaceutical industry.

FDA approves Roche's Avastin for ovarian cancer

By Associated Press  |  November 14, 2014

Swiss drugmaker Roche said Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer. Roche said the FDA approved Avastin in combination with chemotherapy as a treatment for recurrent cases of cancer that are resistant to platinum-based chemotherapy.

Voters nix California healthcare initiatives, approve measures in other states

By Adam Rubenfire and Steven Ross Johnson  |  November 08, 2014

Voters in a number of states decided on a variety of hotly contested state ballot initiatives last week, including measures to regulate health insurance rate increases, hike medical liability damage caps, restrict abortions, make experimental medical treatments more available to patients, and...

Five states now have

Five states now have "right-to-try" laws

By Modern Healthcare  |  November 05, 2014

On Nov. 4 voters in Arizona overwhelmingly approved a referendum for the state to allow terminally ill patients to get drugs and devices that have completed the Food and Drug Administration's Phase One clinical trials but are still in the investigational stage.

For the dying, state laws offer hope that critics call hollow

By Steven Ross Johnson  |  November 05, 2014

Amid a tidal wave of Republican election wins, supporters of so-called right-to-try laws claimed victory as Arizona overwhelmingly approved a measure that will allow dying patients to get drugs and medical devices not yet approved by the Food and Drug Administration.

Advertisement
Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It’s the only news you need each day.

Sponsored by